Baxfendy (baxdrostat) is a first-in-class oral therapy approved for adults with uncontrolled hypertension and resistant high blood pressure. The drug selectively inhibits aldosterone synthase, reducing excess aldosterone production, a key factor associated with persistent hypertension and increased cardiovascular risk.

By targeting a hormonal pathway often overlooked by conventional blood pressure medications, Baxfendy introduces a new approach to hypertension management and cardiovascular disease prevention. Its innovative mechanism may help patients achieve better blood pressure control while reducing the long-term risk of heart attack, stroke, and other cardiovascular complications.